BRAF and metastatic malignant neoplasm in the lymph nodes: Notably, RCS analysis revealed a nonlinear dose–response relationship between BRAF V600E mutation abundance and CLNM risk: as abundance increased from a low level to approximately 20.7%, the risk of lymph node metastasis rose rapidly, whereas beyond this threshold the risk tended to plateau or even slightly decline.